journal article·2025-08-06

Inhalable Mucus-Penetrating Engineered Hybrid Nanomedicine for Enhanced Treatment of Idiopathic Pulmonary Fibrosis

Jinglin Zou, Cong Jiang, Jing Zhang, Shiyue Wan, Yuzi Yang, Yuheng Leng, Shuqi Wang, Xinlin Jia, Yuanqing Mao, Dapeng Zhang, Yongsheng Li

Nano Letters· Volume 25· Issue 31
Publisher page

Abstract

Idiopathic pulmonary fibrosis (IPF) is a life-threatening interstitial lung disease and is one of the complications observed in individuals following COVID-19 infection. Although inhalable nanomedicines hold promise, nebulization-induced shear stress, dense airway mucus barrier, and inefficient in vivo clearance substantially compromise nanomedicine delivery efficiency and biosafety, thereby limiting their therapeutic efficacies. Herein, an inhalable microenvironment-responsive hybrid nanomedicine (PFD@FPNs-CAT) encapsulated with pirfenidone (PFD) and modified with catalase (CAT) is developed, which is able to overcome the supramolecular interactions owing to the small particle size, electronegativity, and PEGylated surface, thus enhancing the accumulation of PFD@FPNs-CAT in the lesions. Moreover, the surface-anchored CAT is demonstrated to relieve hypoxia, thus reversing the immunosuppressive microenvironment and further enhancing the therapeutic efficacy against IPF. Notably, due to the relatively low quantity of silica doping, PFD@FPNs-CAT demonstrates high stability and excellent biocompatibility. This inhalable mucus-penetrating nanomedicine remarkably inhibits the progression of IPF, illuminating the bright prospects for IPF therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Inhalation and Respiratory Drug Delivery · Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis · Occupational exposure and asthma

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Lab of Low-Dimensional Materials Chemistry, Key Laboratory for Ultrafine Materials of Ministry of Education, Frontier Science Center of the Materials Biology and Dynamic Chemistry, Shanghai Engineering Research Center of Hierarchical Nanomaterials, School of Materials Science and Engineering

East China University of Science and Technology

Department of Thoracic Surgery, Shanghai Pulmonary Hospital

Tongji University School of Medicine

Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery, Shanghai Ninth People’s Hospital

Shanghai Jiao Tong University School of Medicine

Funding

National Key Research and Development Program of China · Science and Technology Commission of Shanghai Municipality · National Natural Science Foundation of China · Shanghai Municipality

References (52)

Show source-provided references
1. 10.1016/S0140-6736(17)30866-810.1016/S0140-6736(17)30866-8 ↗
2. 10.1016/S0140-6736(11)60052-410.1016/S0140-6736(11)60052-4 ↗
3. 10.1016/j.addr.2023.11514710.1016/j.addr.2023.115147 ↗
4. 10.1016/S2213-2600(15)00140-X10.1016/S2213-2600(15)00140-X ↗
5. 10.1183/09031936.0018511410.1183/09031936.00185114 ↗
6. 10.1016/j.cell.2021.11.03310.1016/j.cell.2021.11.033 ↗
7. 10.1038/nrd.2017.17010.1038/nrd.2017.170 ↗
8. 10.1056/NEJMra170575110.1056/NEJMra1705751 ↗
9. 10.1016/j.jconrel.2022.09.05410.1016/j.jconrel.2022.09.054 ↗
10. 10.1056/NEJMoa111335410.1056/NEJMoa1113354 ↗
11. 10.1164/rccm.202112-2824OC10.1164/rccm.202112-2824OC ↗
12. 10.1016/j.resinv.2018.03.00310.1016/j.resinv.2018.03.003 ↗
13. 10.1038/aps.2017.3410.1038/aps.2017.34 ↗
14. 10.1016/j.addr.2020.07.00610.1016/j.addr.2020.07.006 ↗
15. 10.1021/acsami.3c1367710.1021/acsami.3c13677 ↗
16. 10.1002/smll.20230893610.1002/smll.202308936 ↗
17. 10.1002/advs.20230163510.1002/advs.202301635 ↗
18. 10.1038/s41467-019-13094-510.1038/s41467-019-13094-5 ↗
19. 10.1016/j.biomaterials.2009.03.01010.1016/j.biomaterials.2009.03.010 ↗
20. 10.1021/acs.langmuir.9b0043410.1021/acs.langmuir.9b00434 ↗
21. 10.1021/acsnano.4c0076810.1021/acsnano.4c00768 ↗
22. 10.1038/s41565-023-01548-310.1038/s41565-023-01548-3 ↗
23. 10.1038/s41551-021-00786-x10.1038/s41551-021-00786-x ↗
24. 10.1016/j.addr.2022.11430910.1016/j.addr.2022.114309 ↗
25. 10.1056/NEJMra091006110.1056/NEJMra0910061 ↗
26. 10.1021/acsami.7b1499210.1021/acsami.7b14992 ↗
27. 10.1073/pnas.091174810710.1073/pnas.0911748107 ↗
28. 10.1016/j.jconrel.2016.05.03110.1016/j.jconrel.2016.05.031 ↗
29. 10.1016/j.jconrel.2014.06.05510.1016/j.jconrel.2014.06.055 ↗
30. 10.1126/sciadv.160155610.1126/sciadv.1601556 ↗
31. 10.1002/adfm.20200896010.1002/adfm.202008960 ↗
32. 10.1016/j.jconrel.2014.01.00710.1016/j.jconrel.2014.01.007 ↗
33. 10.1002/adhm.20240108510.1002/adhm.202401085 ↗
34. 10.1152/ajplung.00009.200910.1152/ajplung.00009.2009 ↗
35. 10.1124/jpet.109.15304910.1124/jpet.109.153049 ↗
36. 10.1038/s41467-024-55658-010.1038/s41467-024-55658-0 ↗
37. 10.1016/j.apsusc.2017.05.11710.1016/j.apsusc.2017.05.117 ↗
38. 10.1126/sciadv.abn716210.1126/sciadv.abn7162 ↗
39. 10.1038/s41467-020-18047-x10.1038/s41467-020-18047-x ↗
40. 10.1038/s41419-021-04365-510.1038/s41419-021-04365-5 ↗
41. 10.1016/j.matt.2020.05.01710.1016/j.matt.2020.05.017 ↗
42. 10.1016/j.pharmthera.2020.10779810.1016/j.pharmthera.2020.107798 ↗
43. 10.1186/s12931-017-0698-310.1186/s12931-017-0698-3 ↗
44. 10.1016/j.copbio.2003.08.00610.1016/j.copbio.2003.08.006 ↗
45. 10.3390/biomedicines1011287210.3390/biomedicines10112872 ↗
46. 10.1038/s41467-018-07698-610.1038/s41467-018-07698-6 ↗
47. 10.2144/00011272910.2144/000112729 ↗
48. 10.1183/13993003.00864-202110.1183/13993003.00864-2021 ↗
49. 10.1016/j.addr.2020.12.01410.1016/j.addr.2020.12.014 ↗
50. 10.1002/adma.20200417210.1002/adma.202004172 ↗
51. 10.1126/sciadv.abb607510.1126/sciadv.abb6075 ↗
52. 10.1038/mt.2016.3610.1038/mt.2016.36 ↗